On August 7th, Zaiding Pharmaceutical announced its financial performance for the second quarter of 2024. The net product revenue for the second quarter was $100.1 million, a year-on-year increase of 45%; Calculated at a fixed exchange rate, it increased by 47% year-on-year. The net loss for the second quarter was $80.3 million, with a loss of $0.08 per ordinary share. The net loss for the same period in 2023 was $120.9 million, with a loss of $0.13 per ordinary share.